HilleVax, Inc. (HLVX)
NASDAQ: HLVX · Real-Time Price · USD
2.120
+0.030 (1.44%)
Jul 31, 2025, 4:00 PM - Market closed
Company Description
HilleVax, Inc., a clinical-stage biopharmaceutical company, develops and commercializes vaccines in the United States.
The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.
It has a license agreement with Takeda Vaccines, Inc. to develop and commercialize HIL-214 pharmaceutical products.
The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021.
HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.
HilleVax, Inc.
| Country | United States |
| Founded | 2020 |
| IPO Date | Apr 29, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Robert Hershberg |
Contact Details
Address: 321 Harrison Avenue, 5th Fl. Boston, Massachusetts 02118 United States | |
| Phone | 617 213 5054 |
| Website | hillevax.com |
Stock Details
| Ticker Symbol | HLVX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001888012 |
| CUSIP Number | 43157M102 |
| ISIN Number | US43157M1027 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Robert M. Hershberg M.D., Ph.D. | Co-Founder, President, Chief Executive Officer and Chairman of the Board |
| Dr. Aditya Kohli Ph.D. | Co-Founder and Director |
| Shane A. Maltbie | Chief Financial Officer and Treasurer |
| Dr. Anju Chatterji Ph.D. | Chief Technology Officer |
| Paul S. Bavier J.D. | General Counsel, Secretary and Chief Administrative Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 24, 2025 | SCHEDULE 13G | Filing |
| Jun 25, 2025 | 8-K | Current Report |
| May 8, 2025 | 10-Q | Quarterly Report |
| May 8, 2025 | 8-K | Current Report |
| May 2, 2025 | SCHEDULE 13D | Filing |
| Apr 30, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 30, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 30, 2025 | ARS | Filing |
| Mar 28, 2025 | 10-K | Annual Report |
| Mar 28, 2025 | 8-K | Current Report |